Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on precision genetic medicines through base editing, has announced its participation in three major investor conferences in September 2025.
The company's management will engage in fireside chats at Citi's 2025 Biopharma Back to School Conference (September 3), the 2025 Wells Fargo Healthcare Conference (September 4), and the H.C. Wainwright 27th Annual Global Investment Conference (September 8). All presentations will be available via webcast on the company's investor relations website for 60 days following each event.
Beam Therapeutics (Nasdaq: BEAM), azienda biotecnologica specializzata in terapie genetiche di precisione tramite base editing, ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settembre 2025.
Il management terrà interventi in formato fireside chat al Citi's 2025 Biopharma Back to School Conference (3 settembre), al 2025 Wells Fargo Healthcare Conference (4 settembre) e al H.C. Wainwright 27th Annual Global Investment Conference (8 settembre). Tutte le presentazioni saranno disponibili in webcast sul sito web investor relations della società per 60 giorni dopo ciascun evento.
Beam Therapeutics (Nasdaq: BEAM), una compañía biotecnológica centrada en medicinas genéticas de precisión mediante base editing, ha anunciado su participación en tres importantes conferencias para inversores en septiembre de 2025.
La dirección participará en charlas informales (fireside chats) en el Citi's 2025 Biopharma Back to School Conference (3 de septiembre), en el 2025 Wells Fargo Healthcare Conference (4 de septiembre) y en el H.C. Wainwright 27th Annual Global Investment Conference (8 de septiembre). Todas las presentaciones estarán disponibles por webcast en la web de relaciones con inversores de la compañía durante 60 días tras cada evento.
Beam Therapeutics (Nasdaq: BEAM)는 베이스 에디팅을 통한 정밀 유전자 치료제 개발에 주력하는 생명공학 회사로, 2025년 9월에 열리는 주요 투자자 컨퍼런스 세 곳에 참가한다고 발표했습니다.
경영진은 Citi's 2025 Biopharma Back to School Conference(9월 3일), 2025 Wells Fargo Healthcare Conference(9월 4일), H.C. Wainwright 27th Annual Global Investment Conference(9월 8일)에서 파이어사이드 채트(fireside chat)에 참여합니다. 모든 발표는 각 행사 종료 후 60일간 회사 투자자 관계 웹사이트에서 웹캐스트로 시청할 수 있습니다.
Beam Therapeutics (Nasdaq: BEAM), une société de biotechnologie spécialisée dans les médecines génétiques de précision par base editing, a annoncé sa participation à trois grandes conférences pour investisseurs en septembre 2025.
La direction prendra part à des 'fireside chats' lors du Citi's 2025 Biopharma Back to School Conference (3 septembre), du 2025 Wells Fargo Healthcare Conference (4 septembre) et du H.C. Wainwright 27th Annual Global Investment Conference (8 septembre). Toutes les présentations seront disponibles en webcast sur le site relations investisseurs de la société pendant 60 jours après chaque événement.
Beam Therapeutics (Nasdaq: BEAM), ein Biotechnologieunternehmen, das sich auf präzise Gentherapien mittels Base Editing spezialisiert, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im September 2025 bekanntgegeben.
Das Management wird an Fireside-Chats beim Citi's 2025 Biopharma Back to School Conference (3. September), beim 2025 Wells Fargo Healthcare Conference (4. September) und beim H.C. Wainwright 27th Annual Global Investment Conference (8. September) teilnehmen. Alle Präsentationen werden ab jeweils nach dem Ereignis für 60 Tage per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
- Citi’s 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, at 4:00 p.m. ET in Boston
- 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025, at 1:30 p.m. ET in Boston
- H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 10:30 a.m. ET in New York
The live webcasts will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contacts:
Investors:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
FAQ
When is Beam Therapeutics (BEAM) presenting at the Citi Biopharma Conference 2025?
How can investors access Beam Therapeutics' (BEAM) September 2025 conference presentations?
What conferences is Beam Therapeutics (BEAM) attending in September 2025?
What time is Beam Therapeutics' (BEAM) presentation at the 2025 Wells Fargo Healthcare Conference?
